Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy | Zendy

Gareth Murcutt | Zendy; Jessica K. Edwards | Zendy; Jessica Dufie Boakye | Zendy; Andrew Davenport | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy

Author(s) -

Gareth Murcutt,

Jessica K. Edwards,

Jessica Dufie Boakye,

Andrew Davenport

Publication year - 2008

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2008.95

Subject(s) - medicine , dialysis therapy , hemodialysis , kidney disease , dialysis , ablative case , clearance , thyroid cancer , radiation therapy , artificial kidney , urology , thyroid , surgery , intensive care medicine

Ablative radioiodine therapy is the standard treatment for thyroid carcinoma, but as (131)I is predominantly cleared by renal excretion, its clearance will be reduced in patients with chronic kidney disease, particularly in anuric patients on dialysis. The high dose of radioactivity used in the procedure results in an increased risk of radioactive exposure to the patient, the dialysis staff, and the machinery. Here, we describe how to successfully hemodialyze patients with chronic kidney failure requiring ablative (131)I therapy for thyroid cancer while minimizing risks to the patient and dialysis staff. With appropriate training, hemodialysis treatments can be safely delivered to patients receiving radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research